By Katherine Hamilton
Omnicell shares fell after the company lowered its guidance due to expected costs and uncertainty from tariffs.
The stock slid 15% to $26.01 on Tuesday morning, at one point touching a 52-week low of $22.66. Shares have lost roughly 43% of their value this year.
The healthcare-technology company, which automates medication management for hospitals and pharmacies, on Tuesday reduced its full-year guidance to account for higher supply-chain costs from tariffs.
Omnicell is now expecting $1.00 to $1.65 in adjusted earnings per share for all of 2025, down from prior guidance of $1.65 to $1.85. Revenue guidance was unchanged.
Chief Executive Randall Lipps said the company is implementing strategies to mitigate potential tariff-related costs, but that uncertainty about those impacts compelled management to lower guidance.
In the first quarter, Omnicell narrowed its loss to $7 million, or 15 cents a share, from its prior-year loss of $15.7 million, or 34 cents a share. Adjusted earnings were 26 cents a share, ahead of the 20 cents a share forecast by Wall Street.
Revenue in the first quarter rose 10% to $269.7 million, ahead of the $259.9 million expected by analysts, according to FactSet.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 06, 2025 10:25 ET (14:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.